0001096906-21-002587.txt : 20211026 0001096906-21-002587.hdr.sgml : 20211026 20211026150222 ACCESSION NUMBER: 0001096906-21-002587 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211026 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12575 FILM NUMBER: 211347890 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 8-K 1 utmd-20211026.htm UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing
0000706698 false 0000706698 2021-10-26 2021-10-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported):  October 26, 2021

 

 

UTAH MEDICAL PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Utah

 

000-12575

 

87-0342734

(State or other jurisdiction of

 

(Commission File Number)

 

(IRS Employer

incorporation or organization)

 

 

 

Identification No.)

 

 

 

 

 

7043 South 300 West

 

 

Midvale, Utah

 

84047

(Address of principal executive offices)

 

(Zip code)

 

 

 

Registrant’s telephone number, including area code:  

 

Phone: (801) 566-1200

 

 

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION

 

Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended September 30, 2021 and forward-looking statements relating to 2021 and beyond as presented in a press release dated October 26, 2021.  The information in this report shall be deemed incorporated by reference into any registration statement heretofore or hereafter filed under the Securities Act of 1933, as amended, except to the extent that such information is superseded by information as of a subsequent date that is included in or incorporated by reference into such registration statement. The information in this report shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.

 

 

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

 

The following is filed as an exhibit to this report:  

 

_______________________________________

*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

UTAH MEDICAL PRODUCTS, INC.

 

 

 

 

 

 

Dated: October 26, 2021

By:

/s/ Kevin L. Cornwell

 

 

Kevin L. Cornwell, Chief Executive Officer

 EX-99.1 2 utah_ex99z1.htm FINANCIAL INFORMATION

EXHIBIT 99.1

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2021

Contact: Crystal Rios (801) 566-1200

October 26, 2021

 

Salt Lake City, Utah – The third calendar quarter (3Q) of 2021 financial results continued to demonstrate Utah Medical Products, Inc.’s (Nasdaq: UTMD’s) recovery after a time when there were restrictions on so-called nonessential medical procedures during the COVID-19 pandemic. Because of the unusual dip in 2020 demand for its devices, UTMD management continues to report quarterly income statement results compared to the same periods not only in 2021 compared to 2020, but also compared to 2019. The Company is exceeding its stated objective in 2021 to try to fully recover back to its 2019 financial performance. Please see the income statements for all three years on the last page.

 

Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted.  

 

Overview of Results

The following summary comparison of 3Q and first nine months (9M) of 2021 with 3Q and 9M 2020 income statement measures demonstrates UTMD’s excellent recovery, despite many new challenges:

 

 

 

3Q

 

 

9M

2021 to 2020 Comparison

  

(July – September)

 

  

(January-September)

Revenues (Sales):

 

+ 20%

 

 

+ 20%

Gross Profit (GP):

 

+ 24%

 

 

+ 25%

Operating Income (OI):

 

+ 42%

 

 

+ 46%

Income Before Tax (EBT):

 

+ 44%

 

 

+ 45%

Net Income (NI):

 

+ 43%

 

 

+ 44%

Earnings Per Share (EPS):

  

+ 43%

  

  

+ 45%

 

As longer-term UTMD stockholders appreciate, the above dramatic increases resulted from comparing 2021 financial results with the former depressed COVID-19 pandemic year in which so-called “nonessential” medical procedures using UTMD’s devices were restricted by government fiat.  Perhaps the following comparison of 3Q and first nine months (9M) of 2021 with 3Q and 9M 2019, prior to the 2020 pandemic year, might be more meaningful:

 

 

 

3Q

 

9M

2021 to 2019 Comparison

  

(July – September)

 

(January-September)

Revenues (Sales):

 

+ 1%

 

+ 3%

Gross Profit (GP):

 

+ 9%

 

+ 5%

Operating Income (OI):

 

+ 17%

 

+ 6%

Income Before Tax (EBT):

 

+ 16%

 

+ 6%

Net Income (NI):

 

+ 14%

 

+ 3%

Earnings Per Share (EPS):

  

+ 16%

 

+ 5%

 

The above increases in NI and EPS according to U.S. Generally Accepted Accounting Principles (US GAAP) in both 9M 2021 and 9M 2020 (but not in 3Q 2021 or 3Q 2020, nor in 3Q 2019 and 9M 2019) were affected by long term deferred tax liability (DTL) increases on the balance of Femcare identifiable intangible assets (IIA) due to future changes enacted in UK tax rates. As stockholders may remember, the DTL was initiated as of the 2011 acquisition of Femcare because the expense from amortizing Femcare IIA, most of which is occurring over a fifteen year time span from the acquisition date, is not tax-deductible in the UK. According to US GAAP, the future tax impact of a change in DTL must be recognized in the quarter in which a tax law change is enacted. In 2Q 2020, a $225 increase in deferred UK

taxes over the next six years occurred because the UK decided to not reduce its corporate income tax rate from 19% to 17% beginning in 2Q 2020, as was previously enacted. This year in 2Q 2021, another $390 increase in DTL over the remaining five years occurred because in June 2021, UK parliament ratified the Finance Minister’s plan to increase the UK corporate income tax rate from 19% to 25% beginning on April 1, 2023, which affects the deferred taxes for IIA to be amortized after April 1, 2023 until fully amortized as of 1Q 2026.

 

UTMD management believes that the presentation of results excluding the unfavorable deferred tax liability adjustments to its 9M 2021 and 9M 2020 income tax provisions provide meaningful supplemental information to both management and investors that is more clearly indicative of UTMD’s operating results. The non-US GAAP exclusion only affects Net Income and Earnings Per Share.

 

Excluding the 2Q 2020 and 2Q 2021 deferred tax liability increases and resulting “one-time” tax provision increases due to the UK income tax rate changes, the resulting non-US GAAP 9M NI and EPS changes follow:

 

9M 2021 to 9M 2020

 

(January-September)

NI (non-US GAAP):

+ 45%

EPS (non-US GAAP):

+ 46%

 

In brief, the 3Q and 9M 2021 financial results continue to confirm that, after surviving a depression in its business in 2020, UTMD is back on track, notwithstanding possible future restrictions on healthcare which benefits from the use of UTMD’s medical devices, or other consequences of recent government policies that are having a negative impact on the free market, medical device industry and small businesses in particular.

 

Sales in all product categories and almost all distribution channels were up substantially in 3Q and 9M 2021 compared to the same periods in 2020. Sales invoiced in foreign currencies, which represented 27% of total consolidated sales (when expressed in USD) during both 3Q 2021 and 9M 2021, were helped by a weaker USD.  Consolidated USD sales in 3Q were 0.7% higher, and in 9M 2021 were 1.9% higher, to that which would have resulted using the same foreign currency exchange (FX) rates as in the prior year’s same periods (“constant currency sales”).  

 

Profit margins in 3Q and 9M 2021 compared to 3Q and 9M 2020 follow:

 

 

 

3Q 2021
(Jul – Sep)

 

3Q 2020
(Jul – Sep)

 

9M 2021
(Jan – Sep)

 

9M 2020
(Jan – Sep)

Gross Profit Margin (GP/ sales):

  

64.2%

 

62.0%

 

63.1%

 

60.6%

Operating Income Margin (OI/ sales):

 

40.6%

 

34.2%

 

38.0%

 

31.3%

Net Income Margin (US GAAP)

 

33.5%

 

28.0%

 

29.5%

 

24.5%

Net Income Margin (Non-US GAAP, B4 DTL Adj):

  

33.5%

 

28.0%

 

30.6%

 

25.2%

 

Note:  The Net Income Margin is NI, after subtracting a provision for taxes, divided by sales.

 

In 2020, because the Company did not make drastic cuts to its operating overheads to try to match the lower sales activity, profit margins suffered relative to UTMD’s performance in prior years, but still remained very solid in regard to UTMD’s ability to remain viable during the pandemic. The decision to not cut back was based on management’s belief that most overhead expenses represented critical resources needed to support the business as it was expected to recover, together with the comfort of UTMD’s cash reserves.  Profit margins in 2021 have returned to levels more consistent with longer term management expectations.

UTMD’s September 30, 2021 Balance Sheet, in the absence of debt, continued to strengthen. Ending Cash and Investments were $64.3 million on September 30, 2021 compared to $51.6 million on December 31, 2020, after paying $3.1 million in cash dividends to stockholders during 9M 2021.  UTMD’s cash balance increased $18 million, or $4.94/ outstanding share at September 30, 2021 from one year earlier, after paying $1.14/ share during that same twelve month period. Stockholders’ Equity (SE) increased $7.2 million in the nine month period from December 31, 2020 despite the fact that dividends reduce SE.  Compared to September 30, 2020, one year earlier, SE increased $11.6 million.

 

Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 3Q 2021 compared to the end of calendar year 2020 and the end of 3Q 2020 follow:

 

 

 

9-30-21

 

12-31-20

 

Change

 

9-30-20

 

Change

GBP

 

1.34676

 

1.36631

 

(1.4%)

 

1.29175

 

4.3%

EUR

 

1.15770

 

1.22281

 

(5.3%)

 

1.17238

 

(1.3%)

AUD

 

0.72284

 

0.77079

 

(6.2%)

 

0.71614

 

0.9%

CAD

  

0.78908

  

0.78406

  

0.6%

  

0.75056

  

5.1%

 

Revenues (sales) -3Q 2021

Total consolidated 3Q 2021 UTMD worldwide (WW) sales were $2,094 (+20.0%) higher than in 3Q 2020. Constant currency sales were $2,006 (+19.1%) higher. U.S. domestic sales were 11% higher and outside the U.S. (OUS) sales were 37% higher. Without the help of a weaker USD in converting foreign currency sales, OUS sales were 34% higher (i.e. constant currency sales). In 3Q 2021, after lagging in 1H 2021 improvement, OUS sales began to catch up with U.S. domestic sales. Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole.

 

Domestic U.S. sales in 3Q 2021 were $7,749 compared to $6,950 in 3Q 2020.  Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) “direct other device sales” of UTMD’s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) “OEM sales” of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) “direct Filshie device sales”. UTMD separates Filshie device sales from other medical device sales direct to medical facilities because of their significance, and the acquisition history. Direct other device sales, representing 48% of total domestic sales, were $277 (+8%) higher in 3Q 2021 than in 3Q 2020. OEM sales, representing 32% of total domestic sales, were $704 (+40%) higher. Direct Filshie device sales, representing 20% of total domestic sales, were $182 (10%) lower in 3Q 2021 compared to 3Q 2020.

 

OUS sales in 3Q 2021 were 37% higher at $4,823 compared to $3,528 in 3Q 2020. The increase in USD-denominated OUS sales was enhanced as a result of a weaker USD which added $88 to OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies (in constant currency terms).  “Constant currency” sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 3Q 2021 and 3Q 2020 for revenue purposes follow:

 

 

 

3Q 2021

 

3Q 2020

 

Change

GBP

 

1.3785

 

1.2948

 

+ 6.5%

EUR

 

1.1793

 

1.1729

 

+ 0.6%

AUD

 

0.7348

 

0.7144

 

+ 2.9%

CAD

  

0.7941

 

0.7513

 

+ 5.7%

The weighted average favorable impact on 3Q 2021 foreign currency OUS sales was 2.7%, increasing reported USD sales by $88 relative to the same foreign currency sales in 3Q 2020.  In constant currency terms, foreign currency sales in 3Q 2021 were 48% higher than in 3Q 2020. The portion of OUS sales invoiced in foreign currencies in USD terms were 27% of total consolidated 3Q 2021 sales compared to 21% in 3Q 2020.   

 

OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK.  Export sales from the U.S. to OUS distributors are invoiced in USD.  Direct to end-user OUS 3Q 2021 sales in USD terms were 9% higher in Ireland, 8% lower in Canada, 4% higher in France and 38% higher in the UK than in 3Q 2020. Direct to end-user sales in Australia, which included New Zealand in 3Q 2021 but not in 3Q 2020, were 23% higher. Sales to OUS distributors were 56% higher in 3Q 2021 than in 3Q 2020.

 

Sales -9M 2021

Total consolidated 9M 2021 UTMD worldwide (WW) sales were $5,972 (+19.8%) higher than in 9M 2020. Constant currency sales were $5,303 (+17.6%) higher than in 9M 2020. U.S. domestic sales were 19% higher and OUS sales were 21% higher. Without the help of a weaker USD in converting foreign currency sales, OUS sales were 15% higher.

 

Domestic U.S. sales in 9M 2021 were $22,555 compared to $18,906 in 9M 2020.  Direct other device sales, representing 48% of total domestic sales, were $1,229 (+13%) higher in 9M 2021 than in 9M 2020. OEM sales, representing 31% of total domestic sales, were $2,350 (+50%) higher. Direct Filshie device sales, representing 21% of total domestic sales, were $69 (+2%) higher in 9M 2021 compared to 9M 2020.

 

OUS sales in 9M 2021 were 21% higher at $13,585 compared to $11,262 in 9M 2020. The increase in USD-denominated OUS sales was enhanced as a result of a weaker USD which added $669 to OUS sales that were invoiced in GBP, EUR, AUD and CAD foreign currencies (in constant currency terms).  FX rates for income statement purposes are transaction-weighted averages. The weighted-average FX rates from the applicable foreign currency to USD during 9M 2021 and 9M 2020 for revenue purposes follow:

 

 

 

9M 2021

 

9M 2020

 

Change

GBP

 

1.3860

 

1.2793

 

+ 8.3%

EUR

 

1.1957

 

1.1276

 

+ 6.0%

AUD

 

0.7584

 

0.6773

 

+12.0%

CAD

  

0.7985

 

0.7449

 

+ 7.2%

 

The weighted-average favorable impact on 9M 2021 foreign currency OUS sales was 7.4%, increasing reported USD sales by $669 relative to the same foreign currency sales in 9M 2020.  In constant currency terms, OUS sales in 9M 2021 were 14.7% higher than in 9M 2020. The portion of OUS sales invoiced in foreign currencies in USD terms was 27% of total consolidated 9M 2021 sales compared to 21% in 9M 2020. Direct to end-user OUS 9M 2021 sales in USD terms were 20% higher in Ireland, 2% higher in Canada, 19% higher in France and 24% higher in the UK.  Direct to end-user sales in Australia, which included New Zealand in 9M 2021 but not in 9M 2020, were 29% higher. Sales to OUS distributors were 22% higher in 9M 2021 than in 9M 2020.

Gross Profit (GP)

GP results from subtracting the costs of manufacturing, quality assurance and receiving materials from suppliers. UTMD’s GP was $1,576 (+24.3%) higher in 3Q 2021 than in 3Q 2020, and $4,522 (+24.7%) higher in 9M 2021 than in 9M 2020.  The primary contribution to an expanded GP Margin (GPM) was much greater dilution of fixed manufacturing overhead costs by 20% higher sales in both 3Q 2021 and 9M 2021. The greater percentage increase in GP than in sales is due to the ability to leverage fixed costs. Incremental direct labor costs did increase as a result of inflationary pressure on wages and competition for a limited number of people currently seeking work. Also during 3Q 2021, UTMD continued to experience double-digit percentage cost increases in a number of raw materials, as well as in the freight cost to receive the materials. The growing administrative burden of compliance with regulatory requirements, particularly OUS, continues to pressure UTMD’s GPM. Managing variable manufacturing costs will continue to be a significant challenge.  

 

Operating Income (OI)

OI results from subtracting Operating Expenses (OE) from GP. After subtracting OE from substantially higher 3Q and 9M 2021 GP, OI in 3Q 2021 was $5,098 compared to $3,588 in 3Q 2020, an increase of 42.1%, and was $13,750 in 9M 2021 compared to $9,428 in 9M 2020, an increase of 45.8%. Despite OE in USD being slightly higher in 2021 than in the same 2020 time periods, as shown in the table below, the period-to-same-period increases in 2021 GP were further leveraged as a result of substantially better OE absorption (lower percentage of sales).

 

OE are comprised of Sales and Marketing (S&M) expenses, General and Administrative (G&A) expenses and Product Development (R&D) expenses. The following table summarizes OE in 3Q and 9M 2021 compared to the same periods in 2020 by OE category:

 

OE
Category

 

3Q 2021

 

% of
sales

 

3Q 2020

 

% of
sales

 

9M 2021

 

% of
sales

 

9M 2020

 

% of
sales

S&M:

 

$324 

 

2.6 

 

$352 

 

3.4 

 

$1,071 

 

3.0 

 

$1,195 

 

4.0 

G&A:

 

2,524 

 

20.1 

 

2,432 

 

23.2 

 

7,598 

 

21.0 

 

7,285 

 

24.2 

R&D:

 

126 

 

1.0 

 

125 

 

1.2 

 

385 

 

1.1 

 

375 

 

1.2 

Total OE:

  

2,974 

 

23.7 

 

2,909 

 

27.8 

 

9,054 

 

25.1 

 

8,855 

 

29.4 

 

Although a weaker USD helped increase consolidated USD sales in 2021, it also helped increase the USD-denominated OE of UTMD’s foreign subsidiaries by $49 in 3Q 2021 and $221 in 9M 2021. The following table summarizes “constant currency” OE in 3Q and 9M 2021 compared to the same periods in 2020 by OE category:

 

OE
Category

 

3Q 2021
const FX

 

        

 

3Q 2020

 

        

 

9M 2021
const FX

 

        

 

9M 2020

 

        

S&M:

 

$321 

 

 

 

$352 

 

 

 

$1,049 

 

 

 

$1,195 

 

 

G&A:

 

2,478 

 

 

 

2,432 

 

 

 

7,400 

 

 

 

7,285 

 

 

R&D:

 

126 

 

 

 

125 

 

 

 

384 

 

 

 

375 

 

 

Total OE:

  

2,925 

 

 

 

2,909 

 

 

 

8,833 

 

 

 

8,855 

 

 

 

In other words, 9M 2021 OE converted to USD at the same FX rate were actually somewhat lower than in 9M 2020.  Holding OE constant while dramatically increasing revenues with a higher GPM had a huge favorable impact on OI.

 

The change in FX rates increased 3Q 2021 OUS S&M expense by $3, and 9M 2021 OUS S&M expense by $23. The lower constant currency S&M expenses were due primarily to a reduction of one sales representative in the U.S.

A division of G&A expenses by location follows. G&A expenses include non-cash expenses from the amortization of IIA associated with the Filshie Clip System, which is also separated out below:

 

G&A Exp
Category

 

3Q 2021

 

% of
sales

 

3Q 2020

 

% of
sales

 

9M 2021

 

% of
sales

 

9M 2020

 

% of
sales

IIA Amort- UK:

 

$548 

 

4.4 

 

$516 

 

4.9 

 

$1,654 

 

4.6 

 

$1,523 

 

5.0 

IIA Amort– CSI:

 

1,105 

 

8.8 

 

1,105 

 

10.5 

 

3,316 

 

9.2 

 

3,316 

 

11.0 

Other– UK:

 

158 

 

 

 

158 

 

 

 

470 

 

 

 

451 

 

 

Other– US:

 

550 

 

 

 

510 

 

 

 

1,663 

 

 

 

1,564 

 

 

IRE:

 

74 

 

 

 

72 

 

 

 

235 

 

 

 

198 

 

 

AUS:

 

48 

 

 

 

38 

 

 

 

136 

 

 

 

126 

 

 

CAN:

 

41 

 

 

 

33 

 

 

 

124 

 

 

 

106 

 

 

Total G&A:

  

2,524 

 

20.1 

 

2,432 

 

23.2 

 

7,598 

 

21.0 

 

7,284 

 

24.1 

 

About two-thirds of G&A expenses in all periods above were from the non-cash expense of amortizing IIA related to the Filshie Clip System. OUS G&A expenses were $869 in 3Q 2021 compared to $817 in 3Q 2020. OUS G&A expenses were $2,619 in 9M 2021 compared to $2,405 in 9M 2020.  The table below identifies constant currency OUS G&A expenses for 3Q and 9M 2021 compared to the same periods in 2020:

 

G&A Exp
Category

 

3Q 2021
const FX

 

3Q 2020

 

9M 2021
const FX

 

9M 2020

 

IIA Amort- UK:

 

$515 

 

$516 

 

$1,528 

 

$1,524 

 

Other– UK:

 

149 

 

158 

 

434 

 

451 

 

IRE:

 

74 

 

72 

 

222 

 

198 

 

AUS:

 

47 

 

38 

 

122 

 

126 

 

CAN:

 

38 

 

33 

 

116 

 

106 

 

Total G&A:

 

823 

 

817 

 

2,422 

 

2,405 

 

 

Period to period product development (R&D) expenses varied slightly depending on specific project costs. Since almost all R&D is being carried out in the U.S., there was negligible FX rate impact.  

 

Income Before Tax (EBT)

EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI.  Consolidated 3Q 2021 EBT was $5,157 (41.0% of sales) compared to $3,588 (34.2% of sales) in 3Q 2020. Consolidated 9M 2021 EBT was $13,880 (38.4% of sales) compared to $9,553 (31.7% of sales) in 9M 2020.     

 

NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company’s technology. Negative NOE is NOI.  Net NOI in 3Q 2021 was $59 compared to $1 NOI in 3Q 2020. Net NOI in 9M 2021 was $130 compared to $126 NOI in 9M 2020.  UTMD realized a $13 remeasured currency balance loss in 9M 2021 compared to a $41 gain in 9M 2020, and despite higher cash balances in 2021 compared to 2020, UTMD received $32 less in interest income. Those differences were offset by NOI generated in Ireland from renting unused warehouse space to a third party, yielding 9M 2021 NOI slightly higher than in 9M 2020.    

EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 3Q 2021 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (“adjusted consolidated EBITDA”) was $7,024 compared to $5,432 in 3Q 2020.  

 

Adjusted consolidated EBITDA was $19,495 in 9M 2021 compared to $15,004 in 9M 2020. Adjusted consolidated EBITDA for the previous four calendar quarters (TTM) was $25,616 as of September 30, 2021.  

 

Based on the better than previously projected 3Q 2021 operating results, management expects adjusted consolidated EBITDA of more than $26 million for the full year 2021, and $28 million in 2022.

 

UTMD’s adjusted consolidated EBITDA as a percentage of sales was 55.9% in 3Q 2021 compared to 51.8% in 3Q 2020.  UTMD’s adjusted consolidated EBITDA as a percentage of sales was 53.9% in 9M 2021 compared to 49.7% in 9M 2020.

 

Achieving substantially higher revenues with an expanded GPM while keeping operating expenses about the same obviously had an extremely positive effect on this key profitability metric.  

 

Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD’s ongoing excellent financial operating performance, as well as its recovery from 2020.

 

UTMD’s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number:

 

 

3Q 2021

3Q 2020

9M 2021

9M 2020

EBT

$5,157 

$3,588 

$13,880 

$9,553  

Depreciation Expense

157 

160 

483 

495  

Femcare IIA Amortization Expense

548 

517 

1,653 

1,523  

CSI IIA Amortization Expense

1,105 

1,105 

3,316 

3,316  

Other Non-Cash Amortization Expense

9 

12 

27 

37  

Stock Option Compensation Expense

41 

49 

123 

121  

Interest Expense

- 

- 

- 

-  

Remeasured Foreign Currency Balances

7 

2 

13 

(41) 

UTMD non-US GAAP EBITDA:

$7,024 

$5,433 

$19,495 

$15,004  

 

Note

All UTMD income statement measures from GP through EBT (and including non-US GAAP adjusted consolidated EBITDA above) for both 2021 and 2020 time periods were unaffected by the enacted changes in the UK corporate income tax rate.

 

Net Income (NI)

NI in 3Q 2021 of $4,206 (33.5% of sales) was 43.4% higher than NI of $2,933 (28.0% of sales) in 3Q 2020. US GAAP NI in 9M 2021 of $10,656 (29.5% of sales) was 44.3% higher than the US GAAP NI of $7,386 (24.5% of sales) in 9M 2020.

 

NI per US GAAP in both 9M periods was affected by an additional tax provision expense required to be recorded in the quarter in which a tax change is enacted, as a result of an adjustment to UTMD’s deferred tax liability (DTL).  The DTL results from the tax effect of not being able to deduct remaining future amortization expense of Femcare IIA.  In 2Q 2020, because the UK reset its corporate tax rate from 17%

to 19% going forward, it caused UTMD to have to book an additional $225 in income taxes that represented the additional tax which would be paid in the UK over the remaining six year life of the 2011 Femcare acquisition IIA, based on a 19% rate. In 2Q 2021, because the UK reset its corporate tax rate from 19% to 25% beginning with 2Q 2023, it caused UTMD to have to book an additional $390 in its 2Q 2021 income tax provision that represents the additional tax which will be paid in the UK over the then remaining five year life of the 2011 Femcare acquisition IIA. Excluding the $390 DTL increase in 2Q 2021 and the $225 DTL increase in 2Q 2020, both of which reduced 9M NI by those same amounts, 9M 2021 non-US GAAP NI was $11,047 (30.6% of sales), 45.1% higher than 9M 2020 non-US GAAP NI of $7,611 (25.2% of sales).

 

The average consolidated income tax provisions (as a % of the same period EBT) per US GAAP in 3Q 2021 and 3Q 2020 were 18.4% and 18.3% respectively, and were 23.2% and 22.7% in 9M 2021 and 9M 2020 respectively. As the 9M tax rates for both 2021 and 2020 periods are not directly related to EBT generated in the same periods, UTMD provides the following tax rates excluding the 2Q 2021 $390 tax provision adjustment and the 2Q 2020 $225 income tax provision adjustment: The resulting non-GAAP income tax provision rates were 20.4% for 9M 2021 and 20.3% for 9M 2020.

 

The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. UTMD has consistently paid millions of dollars in income taxes annually. The basic corporate income tax rates in each of the sovereignties were the same as in the prior year.

 

Earnings per share (EPS).  

Diluted EPS in 3Q 2021 were $1.150 compared to $0.803 in 3Q 2020, a 43.2% increase.  US GAAP diluted EPS in 9M 2021 were $2.915 compared to $2.008 in 9M 2020, a 45.2% increase.  Excluding the “one-time” income tax provision increases due to the DTL adjustments, non-US GAAP diluted EPS in 9M 2021 were $3.021 compared to $2.069 in 9M 2020, a 46.0% increase. The increases in EPS were substantial as a result of the improvement in operating results. Diluted shares were 3,657,733 in 3Q 2021 compared to 3,653,500 in 3Q 2020.  The higher diluted shares in 3Q 2021 were the result of employee options exercised, offset by a slightly lower dilution factor for unexercised options.

 

The number of shares used for calculating 3Q 2021 EPS was higher than September 30, 2021 outstanding shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. Outstanding shares at the end of 3Q 2021 were 3,648,984 compared to 3,643,035 at the end of calendar year 2020. The difference was due to 5,949 shares in employee option exercises during 9M 2021. For comparison, outstanding shares were 3,640,371 at the end of 3Q 2020. The total number of outstanding unexercised employee and outside director options at September 30, 2021 was 59,869 at an average exercise price of $68.74, including shares awarded but not yet vested.  This compares to 71,700 unexercised option shares at the end of 3Q 2020 at an average exercise price of $65.80/ share, including shares awarded but not vested.

 

The number of shares added as a dilution factor for 3Q 2021 was 10,933 compared to 11,130 in 3Q 2020. The number of shares added as a dilution factor for 9M 2021 was 10,685 compared to 14,514 in 9M 2020. In March 2020, 26,300 option shares were awarded to 48 employees at an exercise price of $77.05 per share. No options have been awarded to date in 2021.  UTMD paid $1,039 ($0.285/share) in dividends to stockholders in 3Q 2021 compared to $1,020 ($0.280/ share) paid in 3Q 2020. Dividends paid to stockholders during 3Q 2021 were 25% of NI. UTMD paid $3,116 ($0.285/share) in dividends to stockholders in 9M 2021 compared to $3,097 ($0.280/ share) paid in 9M 2020. The increase in the per share dividend was partially offset by share repurchases in 2020. Dividends paid to stockholders during 9M 2021 were 28% of non-US GAAP NI.

In March 2020, UTMD repurchased 80,000 of its shares in the open market at $80.32/ share. In September 2020, UTMD repurchased 7,000 shares at $78.67/ share.  No shares have been repurchased to date in 2021. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD’s closing share price at the end of 3Q 2021 was $92.84, up from the closing price of $85.04 at the end of 2Q 2021, and the closing price of $84.30 at the end of 2020.    

 

Balance Sheet.

At September 30, 2021 compared to the end of 2020, UTMD’s cash and investments increased $12.7 million to $64.3 million primarily as a result of operating EBITDA less a $3.1 million payment of cash dividends to stockholders, plus some changes in working capital including increases in both accounts receivable from the higher sales activity and current liabilities from higher production activity. At September 30, 2021, Net Intangible Assets decreased to 27.5% of total consolidated assets from 34.1% on December 31, 2020 despite a weaker USD which raises the USD value of Femcare’s GBP IIA.  

 

Financial ratios as of September 30, 2021 which may be of interest to stockholders follow:

1)Current Ratio = 15.1 

2)Days in Trade Receivables (based on 3Q 2021 sales activity) = 34.5 

3)Average Inventory Turns (based on 3Q 2021 CGS) = 2.9 

4)2021 YTD ROE (before dividends) = 14% 

 

Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected.  Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare in general, tax reforms, the Company’s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD’s public disclosure filings with the SEC.  UTMD’s 3Q 2021 SEC Form 10-Q will be filed on or before November 15, 2021, and can be accessed on www.utahmed.com.

 

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients.  For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.

Utah Medical Products, Inc.

 

INCOME STATEMENT, Third Quarter (three months ended September 30)

(in thousands except earnings per share):

 

 

3Q 2021

3Q 2020

Percent Change

3Q 2019

Net Sales

$ 12,572

$10,479

20.0%

$ 12,494

Gross Profit

8,073

6,497

24.3%

7,379

Operating Income

5,098

3,588

42.1%

4,371

Income Before Tax

5,157

3,588

43.7%

4,448

Net Income (US GAAP)

4,206

2,933

43.4%

3,705

Earnings Per Share (US GAAP)

$1.150

$ .803

43.2%

$ .991

Shares Outstanding (diluted)

3,658

3,654

 

3,737

 

INCOME STATEMENT, First Nine Months (nine months ended September 30)

(in thousands except earnings per share):

 

 

9M 2021

9M 2020

Percent Change

9M 2019

Net Sales

$ 36,140

$ 30,168

19.8%

$ 35,073

Gross Profit

22,804

18,283

24.7%

21,652

Operating Income

13,750

9,428

45.8%

12,954

Income Before Tax

13,880

9,553

45.3%

13,150

Net Income before DTL adjust

11,047

7,611

45.1%

10,369

Net Income (US GAAP)

10,656

7,386

44.3%

10,369

EPS before DTL adjustment

$ 3.021

$ 2.069

46.0%

$ 2.774

EPS (US GAAP)

$ 2.915

$ 2.008

45.2%

$ 2.774

Shares Outstanding (diluted)

3,656

3,678

 

3,738

 

BALANCE SHEET

 

(in thousands)

(unaudited)

SEP 30, 2021

(unaudited)

JUN 30, 2021

(audited)

DEC 31, 2020

(unaudited)

SEP 30, 2020

Assets

 

 

 

 

  Cash & Investments

$64,321

$59,506

$51,590

$46,294

  Accounts & Other Receivables, Net

4,853

4,606

4,104

4,277

  Inventories

6,299

6,118

6,222

6,304

  Other Current Assets

373

357

346

385

    Total Current Assets

75,846

70,587

62,262

57,260

Property & Equipment, Net

10,932

11,168

11,326

11,036

Intangible Assets, Net

32,974

35,039

38,157

38,776

       Total Assets

$119,752

$116,794

$111,745

$107,072

Liabilities & Stockholders’ Equity

 

 

 

 

Accounts Payable

$  1,026

$  1,186

$   788

$   651

REPAT Tax Payable

237

245

79

79

Other Accrued Liabilities

3,752

3,000

2,924

2,897

  Total Current Liabilities

 $5,015

 $4,431

 $3,791

 $3,627

Deferred Tax Liability – Intangible Assets

2,196

2,355

2,151

2,132

Long Term Lease Liability

Long Term REPAT Tax Payable

343

1,810

322

1,835

335

1,995

346

1,995

Deferred Revenue and Income Taxes

408

486

651

557

Stockholders’ Equity

109,980

107,365

102,822

98,415

      Total Liabilities & Stockholders’ Equity

$119,752

$116,794

$111,745

$107,072

 EX-101.DEF 3 utmd-20211026_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 utmd-20211026_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Entity Address, State or Province Filer Category Number of common stock shares outstanding Details Entity Address, Postal Zip Code Trading Symbol City Area Code Entity File Number Pre-commencement Issuer Tender Offer Written Communications Entity Address, City or Town Entity Incorporation, State or Country Code Soliciting Material Entity Address, Address Line One Voluntary filer Public Float Local Phone Number Amendment Description Current with reporting Tax Identification Number (TIN) SEC Form Amendment Flag Ex Transition Period Well-known Seasoned Issuer Pre-commencement Tender Offer Small Business Registrant Name Trading Exchange Registrant CIK Shell Company Interactive Data Current Period End date Fiscal Year End Emerging Growth Company EX-101.PRE 5 utmd-20211026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 6 utmd-20211026.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink XML 7 utmd-20211026_htm.xml IDEA: XBRL DOCUMENT 0000706698 2021-10-26 2021-10-26 0000706698 false 8-K 2021-10-26 UTAH MEDICAL PRODUCTS, INC. UT 000-12575 87-0342734 7043 South 300 West Midvale UT 84047 801 566-1200 false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 26, 2021
Details  
Registrant CIK 0000706698
Registrant Name UTAH MEDICAL PRODUCTS, INC.
SEC Form 8-K
Period End date Oct. 26, 2021
Tax Identification Number (TIN) 87-0342734
Emerging Growth Company false
Entity Incorporation, State or Country Code UT
Entity File Number 000-12575
Entity Address, Address Line One 7043 South 300 West
Entity Address, City or Town Midvale
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84047
City Area Code 801
Local Phone Number 566-1200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports utmd-20211026.htm utah_ex99z1.htm utmd-20211026.xsd utmd-20211026_def.xml utmd-20211026_lab.xml utmd-20211026_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "utmd-20211026.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "utmd-20211026_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "utmd-20211026.htm" ] }, "labelLink": { "local": [ "utmd-20211026_lab.xml" ] }, "presentationLink": { "local": [ "utmd-20211026_pre.xml" ] }, "schema": { "local": [ "utmd-20211026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 34, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fil", "nsuri": "http://utahmed.com/20211026", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20211026.htm", "contextRef": "D211026", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010 - Document - Document and Entity Information", "role": "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "utmd-20211026.htm", "contextRef": "D211026", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Fiscal Year End" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Period End date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "SEC Form" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Registrant CIK" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Number of common stock shares outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Current with reporting" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Tax Identification Number (TIN)" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Voluntary filer" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Trading Exchange" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://utahmed.com/20211026/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001096906-21-002587-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001096906-21-002587-xbrl.zip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end